ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET 2019-2027

Lifesciences | Diagnostic & Biotechnology

ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET 2019-2027

Market By Gender, End-use And Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

As per Triton’s research, the Asia-Pacific infertility (testing and treatment) market is evolving at the highest CAGR of 7.80% in terms of revenue over the estimated duration of 2019 to 2027.

Countries considered in the Asia-Pacific infertility (testing and treatment) market are:

•    China

•    India

•    Japan

•    South Korea

•    ASEAN countries

•    Australia & New Zealand

•    Rest of Asia Pacific 

Report scope can be customized per your requirements. Request For Customization

Within the report, the current trends, the market definition, Porter’s five force analysis and the market attractiveness index for infertility (testing and treatment) market have been discussed in detail. 

A significant driving factor for the rising demand for infertility-related treatments is the decrease in the birth rate in some of the major Asian countries such as South Korea and Japan. The present rate of birth in these countries is 1.5 babies per woman. The government in developed countries of the region such as Singapore and South Korea are offering to subsidize the cost of IVF treatment. Indian subcontinent boasts of a high fertility rate as compared to its neighbors. With its current relaxed legal rules for commercial surrogacy, it is a market that should be further explored. An increase in the levels of awareness levels among people is anticipated to boost the market revenues of infertility (testing and treatment) market. 

According to Japan's Association of Obstetricians and Gynecologists, one out of 27 babies born in Japan in 2012 was through test-tube fertilization/IVF. Japan has a very low fertility rate of 1.5 children per woman. Japan is facing a fall in the labor force as a significant proportion of the population in the country has aged. Japanese government offers 50% subsidy on the total cost of IVF treatment to married couples and is now evaluating to extend this to unmarried couples if they are planning for a child using IVF. Reimbursement is a major concern for affected couples. In Asian countries like India and China government doesn’t provide any coverage, couples have to take help of private insurers or pay out of pocket.

The major drivers for the growth of the Indian market are the increase in infertility and the availability of low-cost surrogacy. In India, a considerable percentage of couples suffer from infertility, and issues like pollution, stress, chemical exposure, urbanization, fast-paced and altered lifestyle resulting in delayed pregnancies in women. India has an array of treatment options available for treating infertility including medications for induction of ovulation, endoscopic surgery for correction of anatomical problems and ARTs, including IVF, IUI and ICSI. High level of medical expertise, world-class and advanced technology and a cost-effective healthcare system are some of the reasons that have made India a favorable destination for patients seeking infertility treatments. 

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    INFERTILITY (TESTING AND TREATMENT) MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. KEY INSIGHTS

2.2.1.   IVF DOMINATES THE FEMALE TREATMENT MARKET

2.2.2.   OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET

2.3. PORTER’S FIVE FORCE ANALYSIS

2.3.1.   THREAT OF NEW ENTRANTS

2.3.2.   THREAT OF SUBSTITUTE

2.3.3.   BARGAINING POWER OF BUYERS

2.3.4.   BARGAINING POWER OF SUPPLIERS

2.3.5.   INTENSITY OF COMPETITIVE RIVALRY

2.4. KEY IMPACT ANALYSIS

2.4.1.   TREATMENT OPTIONS

2.4.2.   QUALITY OF MEDICAL PROCEDURES

2.4.3.   PRICE OF TREATMENTS

2.4.4.   SHIFT TOWARDS MEDICAL TOURISM

2.4.5.   REIMBURSEMENT

2.5. MARKET ATTRACTIVENESS INDEX

2.6. VENDOR SCORECARD

2.7. INDUSTRY COMPONENTS

2.7.1.   RAW MATERIAL PROCUREMENT

2.7.2.   MANUFACTURING

2.7.3.   SUPPLY LOGISTICS

2.7.4.   DISTRIBUTION CHANNELS

2.7.5.   END-USERS

2.8. REGULATORY FRAMEWORK

2.9. MARKET DRIVERS

2.9.1.   RISE IN INFERTILITY AND TREATMENT AWARENESS

2.9.2.   MEDICAL TOURISM IN FERTILITY TREATMENTS

2.9.3.   SURROGACY LAWS ARE GETTING MORE DEFINED

2.9.4.   HEALTHCARE ADVANCES HAVE FINE-TUNED FERTILITY TREATMENT

2.9.5.   INCREASING EFFECTIVENESS OF TREATMENTS

2.9.6.   HEALTHIER DONOR EGGS

2.9.7.   INTRODUCTION OF NEW TESTING DEVICES

2.10.            MARKET RESTRAINTS

2.10.1.                TREATMENT PROCEDURE OUT OF REACH FOR MANY DUE TO HIGH COSTS

2.10.2.                COUNTRY-WISE REGULATORY ISSUES

2.11.            MARKET OPPORTUNITIES

2.11.1.                REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE

2.11.2.                IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS

2.11.3.                DIY TESTING INCREASING ACCESS AND REDUCING COST

2.12.            MARKET CHALLENGES

2.12.1.                INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN

2.12.2.                PERILS OF MULTIPLE PREGNANCIES

2.12.3.                TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE FOR INFERTILITY TREATMENTS

3.    INFERTILITY (TESTING AND TREATMENT) MARKET OUTLOOK - BY GENDER

3.1. MALE GENDER

3.1.1.   TESTING

3.1.1.1.      DNA FRAGMENTATION

3.1.1.2.      OXIDATIVE STRESS ANALYSIS

3.1.1.3.      SPERM PENETRATION ASSAY

3.1.1.4.      COMPUTER-ASSISTED SEMEN ANALYSIS (CASA)

3.1.1.5.      SPERM AGGLUTINATION

3.1.1.6.      MICROSCOPIC EXAMINATION

3.1.1.7.      OTHERS

3.1.2.   TREATMENT

3.2. FEMALE GENDER

3.2.1.   FEMALE INFERTILITY TESTING

3.2.1.1.      OVULATION TESTING

3.2.1.2.      HYSTEROSALPINGOGRAPHY

3.2.1.3.      LAPAROSCOPY

3.2.1.4.      TRANSVAGINAL ULTRASOUND

3.2.1.5.      OVARIAN RESERVE TESTING

3.2.1.6.      HORMONAL LEVEL TESTING

3.2.1.7.      OTHERS

3.2.2.   TREATMENT

4.    INFERTILITY (TESTING AND TREATMENT) MARKET OUTLOOK - BY END-USE

4.1. FERTILITY CLINICS

4.2. HOSPITALS

4.3. SURGICAL CENTERS

4.4. CLINICAL RESEARCH INSTITUTES

5.    INFERTILITY (TESTING AND TREATMENT) MARKET - REGIONAL OUTLOOK

5.1.      CHINA

5.2.      JAPAN

5.3.      INDIA

5.4.      SOUTH KOREA

5.5.      ASEAN COUNTRIES

5.6.      AUSTRALIA & NEW ZEALAND

5.7.      REST OF ASIA-PACIFIC

6.    COMPETITIVE LANDSCAPE

6.1. ANDROLOGY SOLUTIONS

6.2. ENDO PHARMACEUTICALS

6.3. PROGYNY

6.4. FERRING PHARMACEUTICALS

6.5. GENEA

6.6. HALOTECH DNA

6.7. IRVINE SCIENTIFIC

6.8. MERCK

6.9. ORIGIO

6.10.            OVASCIENCE

6.11.            VITROLIFE AB        

6.12.            THERMO FISHER SCIENTIFIC, INC.

6.13.            THE COOPER COMPANIES, INC.

6.14.            QUEST DIAGNOSTIC

6.15.            ESCO MICRO PTE. LTD.

7.    RESEARCH METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE & DELIVERABLES

7.1.1.   OBJECTIVES OF STUDY

7.2. SOURCES OF DATA

7.2.1.   PRIMARY DATA SOURCES

7.2.2.   SECONDARY DATA SOURCES

7.3. RESEARCH METHODOLOGY

7.3.1.   EVALUATION OF PROPOSED MARKET

7.3.2.   IDENTIFICATION OF DATA SOURCES

7.3.3.   ASSESSMENT OF MARKET DETERMINANTS

7.3.4.   DATA COLLECTION

7.3.5.   DATA VALIDATION & ANALYSIS

List of table

TABLE 1:       ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)

TABLE 2:       MARKET ATTRACTIVENESS INDEX

TABLE 3:       VENDOR SCORECARD

TABLE 4:       REGULATORY FRAMEWORK

TABLE 5:       AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS

TABLE 6:       ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)

TABLE 7:       GROWTH IN IVF CLINICS IN ASIA

TABLE 8:       ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY GENDER, 2019-2027 (IN $ MILLION)

TABLE 9:       ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY MALE GENDER, 2019-2027 (IN $ MILLION)

TABLE 10:     ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY MALE INFERTILITY TESTING, 2019-2027 (IN $ MILLION)

TABLE 11:     ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE GENDER, 2019-2027 (IN $ MILLION)

TABLE 12:     ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE INFERTILITY TESTING, 2019-2027 (IN $ MILLION)

TABLE 13:     ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY END-USE, 2019-2027 (IN $ MILLION)

TABLE 14:     MEDICAL TOURISM IN SOUTH KOREA ($ MILLION)

List of Figures

FIGURE 1:     ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY END-USER, 2018 & 2027 (IN %)

FIGURE 2:     PORTER’S FIVE FORCE ANALYSIS

FIGURE 3:     KEY BUYING IMPACT ANALYSIS

FIGURE 4:     INDUSTRY COMPONENTS

FIGURE 5:     MAJOR FERTILITY TREATMENT DESTINATION RANKING

FIGURE 6:     CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN

FIGURE 7:     RATE OF MULTIPLE DELIVERIES

FIGURE 8:     ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY MALE GENDER, 2019-2027 (IN $ MILLION)

FIGURE 9:     ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY TESTING, 2019-2027 (IN $ MILLION)

FIGURE 10:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY DNA FRAGMENTATION, 2019-2027 (IN $ MILLION)

FIGURE 11:  CAUSES OF SPERM DNA FRAGMENTATION

FIGURE 12:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY OXIDATIVE STRESS ANALYSIS, 2019-2027 (IN $ MILLION)

FIGURE 13:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY SPERM PENETRATION ASSAY, 2019-2027 (IN $ MILLION)

FIGURE 14:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY COMPUTER-ASSISTED SEMEN ANALYSIS, 2019-2027 (IN $ MILLION)

FIGURE 15:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY SPERM AGGLUTINATION, 2019-2027 (IN $ MILLION)

FIGURE 16:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY MICROSCOPIC EXAMINATION, 2019-2027 (IN $ MILLION)

FIGURE 17:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)

FIGURE 18:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY TREATMENT, 2019-2027 (IN $ MILLION)

FIGURE 19:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE GENDER, 2019-2027 (IN $ MILLION)

FIGURE 20:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE INFERTILITY TESTING, 2019-2027 (IN $ MILLION)

FIGURE 21:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY OVULATION TESTING, 2019-2027 (IN $ MILLION)

FIGURE 22:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY HYSTEROSALPINGOGRAPHY, 2019-2027 (IN $ MILLION)

FIGURE 23:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY LAPAROSCOPY, 2019-2027 (IN $ MILLION)

FIGURE 24:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY TRANSVAGINAL ULTRASOUND, 2019-2027 (IN $ MILLION)

FIGURE 25:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY OVARIAN RESERVE TESTING, 2019-2027 (IN $ MILLION)

FIGURE 26:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY HORMONAL LEVEL TESTING, 2019-2027 (IN $ MILLION)

FIGURE 27:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)

FIGURE 28:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE INFERTILITY TREATMENT, 2019-2027 (IN $ MILLION)

FIGURE 29:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY FERTILITY CLINICS, 2019-2027 (IN $ MILLION)

FIGURE 30:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY HOSPITALS, 2019-2027 (IN $ MILLION)

FIGURE 31:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY SURGICAL CENTERS, 2019-2027 (IN $ MILLION)

FIGURE 32:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, BY CLINICAL RESEARCH INSTITUTES, 2019-2027 (IN $ MILLION)

FIGURE 33:  ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, REGIONAL OUTLOOK, 2018 & 2027 (IN %)

FIGURE 34:  CHINA INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 35:  JAPAN INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 36:  INDIA INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 37:  SOUTH KOREA INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 38:  ASEAN COUNTRIES INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 39:  AUSTRALIA & NEW ZEALAND INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 40:  REST OF ASIA-PACIFIC INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;